RxDoctor Payments DataLook up a doctor →

Lucas Groben, DO

Cardiovascular Disease · West Des Moines, IANPI 1932310018

Payments from drug & device makers

$457,926in general payments, 2019–2025

Across 989 payments — averaging $463.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$281K
  • Boehringer Ingelheim International GmbH$97K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$41K
  • Esperion Therapeutics, Inc.$33K
  • Abbott$4K
  • Boston Scientific$466
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$2,23038%
  • Food & beverage$3,54960%
  • Education$1523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$457,926 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$605,675
Medicare patients
2,289
Services billed
7,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$234,468
XareltoRivaroxaban119$128,290
BrilintaTicagrelor30$13,361
Repatha SureclickEvolocumab13$10,305
MultaqDronedarone Hcl11$8,634
Metoprolol Succinate563$5,664
ClopidogrelClopidogrel Bisulfate420$2,979
Enoxaparin Sodium14$2,607
Atorvastatin Calcium317$2,439
Ranolazine ErRanolazine21$2,158
Dilt-XrDiltiazem Hcl48$1,758
Propafenone Hcl48$1,607
Losartan Potassium296$1,511
Bisoprolol Fumarate92$1,483
Amiodarone Hcl121$1,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$234,468247 claims
Johnson & JohnsonXarelto$26$128,290119 claims
AstraZenecaBrilinta$14$13,36130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →